Johnson & Johnson Aktie News

Added 91,615 shares in Johnson & Johnson; estimated transaction value of ~$15.70 million Trade represents an increase of 2.13% of the fund's reportable U.S. equity AUM Post-trade stake: 102,375 shares valued at $18.98 million as of September 30, 2025 Johnson & Johnson now accounts for 2.58% of CADINHA & CO LLC's reportable equity AUM, placing it outside the fund's top five holdings

Founded in 1869, Goldman Sachs is the world's second-largest investment bank by revenue and is ranked 55th on the Fortune 500 list of the largest United States corporations by total revenue.

Dividend Kings are in a league of their own. These companies have increased their dividends annually for at least the past 50 years.

Responses were rapid and durable, and tumor shrinkage was observed in 82 percent of patients New findings from this investigational study build on the strength of RYBREVANT® (amivantamab-vmjw) in non-small cell lung cancer and broadens its potential across additional solid tumors RARITAN, N.J. , Oct. 19, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced promising new results fro...

Recent market speculation linking Johnson & Johnson NYSE: JNJ to a complete acquisition of its partner, Protagonist Therapeutics NASDAQ: PTGX, offers a valuable glimpse into a core corporate strategy. For a healthcare sector giant of Johnson & Johnson's scale, such moves are not about chasing short-term stock pops.

Jamison Private Wealth Management, Inc. disclosed a purchase of Johnson & Johnson shares valued at $6,762,412 in its SEC filing for the period ended Q3 2025, submitted on October 14, 2025.

First Phase 3 study (MajesTEC-3) of an investigational combination to show benefit in PFS and OS in relapsed/refractory multiple myeloma as early as second line Independent Data Monitoring Committee (IDMC) recommended unblinding the study based on statistically significant results RARITAN, N.J. , Oct. 16, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ), the worldwide leader in multiple myelom...

The idea of steady money flowing in, year after year, should appeal to nearly everyone. This isn't an unrealistic dream; investing in stocks that pay reliable dividends can make it a reality.